Items tagged with Drug-resistant TB

MDR-TB: A ‘global public health crisis’ (post)

TB killed 1.6 million people in 2017 — more than 4,000 each day. Among its deadly attributes, TB is the leading killer of patients with HIV and the cause of one-third of all deaths related to antimicrobial resistance, according to WHO.

'Game changer' TB drug cures 9 in 10 (post)

A new treatment for a drug-resistant strain of tuberculosis can cure more than 90 percent of sufferers, according to a trial hailed Monday (October 22) as a "game changer" in the fight against the global killer.

Improved detection of drug-resistant TB using genetic and culture-based laboratory methods (post)

24 October 2018, New York - WHO and partners released a series of documents today to improve drug susceptibility testing for TB in laboratories worldwide.

Union launches field guide for the management of drug-resistant TB (post)

The Union launched a new technical resource on drug-resistant tuberculosis (DR-TB) management during a press conference on DR-TB at the 49^th Union World Conference on Lung Health, in The Hague, The Netherlands today (October 25).

Public health experts discuss importance of implementing guidelines, improving access to treatment for MDR-TB (post)

Machine learning identifies antibiotic resistance genes in TB-causing bacteria (post)

Researchers at the University of California San Diego have developed an approach that uses machine learning to identify and predict which genes make infectious bacteria resistant to antibiotics. The approach was tested on strains of Mycobacterium tuberculosis—the bacteria that cause tuberculosis (TB) in humans. It identified 33 known and 24 new antibiotic resistance genes in these bacteria.

Nursing Guide for Managing Side Effects to Drug-resistant TB Treatment (post)

Nursing Guide for Managing Side Effects to Drug-resistant TB Treatment is a collaborative project between the Curry International Tuberculosis Center (CITC) and the International Council of Nurses (ICN). The guide was developed by nurses with experience in the clinical care and programmatic management of tuberculosis (TB) and drug-resistant tuberculosis (DR-TB) in both high- and low-resource settings.

90 percent of participants in short-course XDR-TB regimen cured after six months (post)

THE HAGUE, Netherlands – New results from the ongoing Nix-TB trial continue to confirm a short-course treatment regimen of bedaquiline – one of the two newest drugs to treat TB in half a century – linezolid and pretomanid offers a significantly improved treatment option for people infected with drug resistant forms of tuberculosis, researchers said here.

TB patients on bedaquiline have half the mortality of those not on the drug: WHO chief (post)

The WHO will be releasing new recommendations for the treatment of multidrug-resistant and rifampicin-resistant tuberculosis (MDR/RR-TB) later this year, which will speak in more detail about the usage of the new drugs bedaquiline and delamanid.

India: 400 MDR-TB patients in 7 states to get crucial drug (post)

India gets doses of Delamanid from USAID.